Feb. 6 at 7:40 PM
$ACHV H.C. Wainwright views Pfizer’s launch of Chantix among the 30 medicines it placed on the White House’s direct-to-consumer site, TrumpRx, as “a significant positive” for Achieve Life Sciences and cytisinicline, arguing that the news removes the potential of Pfizer bringing Chantix back to market and putting any marketing dollars behind the product.
The move to include Chantix on TrumpRx is “not random or economically driven,” but rather likely a concession to the Make America Healthy Movement within the current administration, which bodes well for the potential for cytisinicline’s chances of approval by the current PDUFA date on June 20, adds the analyst, who has a Buy rating and
$12 price target on Achieve shares.
https://www.tipranks.com/news/the-fly/h-c-wainwright-says-chantix-news-significant-win-for-achieve-life-sciences-thefly
